JNJ-80948543
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for JNJ-80948543, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]